Turn Therapeutics’ Significant Dialogue on Public Trust in Healthcare
Turn Therapeutics Inc. (NASDAQ: TTRX), a notable player in the biotechnology industry, has been making strides in developing groundbreaking treatments for dermatologic issues, advanced wound care, and infectious diseases. Under the leadership of CEO Bradley Burnam, the company is actively engaging with key figures in the healthcare landscape to foster better understanding between science and the public.
Insightful Conversation with Dr. Robert Redfield
In a recent interview, Burnam had the opportunity to converse with Dr. Robert Redfield, M.D., the former Director of the Centers for Disease Control and Prevention. Their discussion focused on a critical topic: how to effectively restore public trust in science and health authorities. This exchange was documented in an interview that can be found on various podcast platforms and YouTube.
Importance of Public Trust
During the conversation, Burnam emphasized the responsibility that not only companies like Turn Therapeutics but also public health authorities have in communicating factual scientific information to the citizens. He quoted Dr. Redfield's longstanding commitment to advocating fact-based science as a backbone of public health, showcasing the need for transparent dialogue in rebuilding trust.
Dr. Redfield’s Background and Contributions
Dr. Redfield, a respected virologist, has contributed significantly to public health, especially during his tenure at the CDC from 2018 to 2021. His efforts included a strong push for decisions grounded in scientific data, demonstrating his investment in public health. Notably, Dr. Redfield made early significant contributions to HIV research, advancing understanding and treatments that have benefited countless individuals.
About Turn Therapeutics and Its Mission
Turn Therapeutics is not just focused on current treatment development but is also committed to future innovations. The company is advancing its development programs particularly in areas like eczema and onychomycosis, boasting three FDA clearances for its proprietary dermatology products. The company’s initiatives extend beyond treatment development; it aims at global health solutions, particularly through its efforts in thermostable vaccine delivery for underserved populations.
Commitment to Innovation
Turn Therapeutics is driven by a dedication to public health innovation. By continuously refining their approaches and embracing strategic partnerships, they are seeking to address not just immediate healthcare needs but also long-term health challenges impacting diverse communities.
Investor Relations and Media Contacts
Investor inquiries can be directed to Monique Kosse, Managing Director at Gilmartin Group, available at Investors@TurnTherapeutics.com. For media-related inquiries, you can reach out to media@TurnTherapeutics.com. Turn Therapeutics is committed to keeping its stakeholders informed and engaged as it advances its programs and initiatives.
Frequently Asked Questions
What is the focus of Turn Therapeutics?
Turn Therapeutics concentrates on developing products for dermatology, advanced wound care, and infectious diseases.
Who did Turn Therapeutics' CEO speak with about public health?
CEO Bradley Burnam spoke with Dr. Robert Redfield, former Director of the CDC, discussing ways to restore trust in science.
What are some achievements of Dr. Redfield?
Dr. Redfield has made several contributions to HIV research and advocated for science-based decision-making during his CDC tenure.
How can investors contact Turn Therapeutics?
Investors can reach out by emailing Investors@TurnTherapeutics.com for inquiries.
What initiatives is Turn Therapeutics pursuing?
The company is engaged in late-stage clinical programs and global health initiatives, particularly in vaccine delivery systems.
